Sugi Predict

Sugi Predict / Compounds / SCHEMBL2949568

SCHEMBL2949568

SCHEMBL2949568

CC(C)(C)NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.61
▸ NPC1 O15118 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ ALDH1A1 P00352 3/20 0.55
▸ LMNA P02545 2/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ TRPA1 O75762 1/20 0.53
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ CNR1 P21554 1/20 0.51
▸ HTT P42858 2/20 0.50
▸ PTGS2 P35354 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ HSD11B1 P28845 1/20 0.49
▸ MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8239994 0.94 POLB (0.56) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL17865779 0.89 LMNA (0.58) POLBSMN1; SMN2LMNAMAPTHTT
SCHEMBL1508016 0.88 POLB (0.50) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL2522600 0.83 LMNA (0.53) POLBSMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL3755534 0.82 POLB (0.56) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL9902474 0.82 EPHX1 (0.71) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL25781021 0.81 L3MBTL1 (0.61) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL8084321 0.81 POLB (0.54) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3750397 0.81 POLB (0.54) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL162828 0.81 TSHR (0.54) SMN1; SMN2ALDH1A1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110229113-B Preparation method of ultraviolet absorbent HEB 湖北师范大学 2022-08-12 — — CN claimed
CN-120081798-A Preparation method of ultraviolet absorber HEB 合肥诺信生物技术有限公司 2025-06-03 — — CN disclosed
CN-118619891-A Method for synthesizing ultraviolet absorber HEB based on copper photocatalysis strategy 武汉纺织大学 2024-09-10 — — CN disclosed
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2023-05-18 — — US disclosed
CN-110229113-B Preparation method of ultraviolet absorbent HEB 湖北师范大学 2022-08-12 — — CN disclosed
CN-110229113-B Preparation method of ultraviolet absorbent HEB 湖北师范大学 2022-08-12 — — CN disclosed
US-9718825-B2 N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals SANOFI (FR) 2017-08-01 — — US disclosed
US-8999977-B2 Bridged heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-07 — — US disclosed
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 — — EP disclosed
US-20130190303-A1 BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 — — US disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 — — US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 — — US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 — — US disclosed
US-7560473-B2 Amine derivative with potassium channel regulatory function, its preparation and use INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES, P.L.A. (CN) 2009-07-14 — — US disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 — — US disclosed
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 — — US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 — — EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 — — US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 — — US disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 POLB 2547/4885NPC1 4272/4885RAB9A 3386/4885
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX POLB 1495/4885NPC1 1477/4885RAB9A 2708/4885
US-20130190303-A1 BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE HRH4, HNMT, HTR2C POLB 4735/4885NPC1 2839/4885RAB9A 648/4885
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 POLB 3216/4885NPC1 300/4885RAB9A 788/4885
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1B, SCN1A, SCN2B POLB 2460/4885NPC1 2158/4885RAB9A 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.